NanoViricides Inc. - NNVC STOCK NEWS

NanoViricides, Inc. (NYSE American: NNVC) announced the initiation of drug development targeting the monkeypox virus. The company plans to screen its broad-spectrum antiviral nanoviricides against poxviruses, aiming to create effective therapeutics. Currently, they are nearing completion of compound synthesis and have established a testing model in their lab. Their ongoing clinical trials for the SARS-CoV-2 drug candidate, NV-CoV-2, are expected to expedite this initiative. There is a pressing need for new treatments, especially as monkeypox cases surge globally.

NanoViricides has filed its quarterly report for Q3 of FY 2022, reporting $16 million in current assets and no revenues. With cash liabilities at approximately $0.4 million, the company's stockholder equity stands at $24.75 million. The firm plans to initiate human clinical trials for its COVID-19 drug candidate, NV-CoV-2, which has shown superior efficacy to remdesivir in animal studies. Additionally, it is developing formulations for oral and inhalation delivery. The company is also working on an antiviral for hAd41-F, related to severe hepatitis cases in children.

NanoViricides, Inc. (NYSE American: NNVC) announced the initiation of drug development targeting human Adenovirus 41 Type F, linked to severe pediatric hepatitis cases. This decision follows a rise in worldwide cases, with over 450 reported, including 110 in the USA, where hospitalization exceeds 90%. The company's priority remains advancing NV-CoV-2, its COVID-19 drug candidate, toward clinical trials. NanoViricides plans to screen its antiviral library against hAd41-F using its own BSL2 Virology facility.

NanoViricides, Inc. (NNVC) provided an update on its COVID-19 drug candidate NV-CoV-2, nearing completion of the Investigators Medicinal Product Dossier for clinical trial application. The drug exhibits a novel 'Re-infection Blocker' mechanism and is effective against emerging SARS-CoV-2 variants. The company reports sufficient funding for Phase I/II trials and has developed Oral Gummies to improve patient compliance. Manufacturing systems for clinical trial products are being rapidly established, and the company aims to produce drugs for 1,000-5,000 patients in a single batch.

NanoViricides, Inc. (NNVC) has filed its quarterly report for Q2 FY2022, indicating about $17.5 million in current assets and $0.34 million in current liabilities as of December 31, 2021. The company reports no revenues and approximately $2.84 million used in operations over the six-month period. It is pursuing clinical trials for its COVID-19 drug candidate, NV-CoV-2, which shows promise in pre-clinical studies, being more effective than remdesivir. Additionally, the company is developing formulations for oral gummies and inhalation to improve drug delivery.

NanoViricides, Inc. has filed its quarterly report for Q1 FY 2022, revealing approximately $19.89 million in current assets and $0.87 million in current cash liabilities, with no debt. The Company reported no revenues during the period. NanoViricides is advancing its drug candidate NV-CoV-2 for COVID-19 treatment, having developed various formulations, including oral gummies and inhalation drugs. The firm has sufficient funds for initial human clinical trials and plans to proceed with IND applications for multiple drug candidates.

NanoViricides, Inc. (NYSE American:NNVC) announced the development of oral gummies and inhalation formulations for its COVID-19 drug candidate NV-CoV-2. These new formulations aim to benefit both non-hospitalized patients and severely ill hospitalized patients. The company reports strong safety results from animal studies, noting that NV-CoV-2 is non-immunogenic, non-allergenic, and non-mutagenic. With these advancements, they aim to support healthcare systems during the ongoing COVID-19 pandemic.

NanoViricides, Inc. (NYSE American:NNVC) filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2021, reporting approximately $20.8 million in cash and cash equivalents and $9.08 million in Property and Equipment. The company raised $10.4 million from an equity offering and $6.1 million under an At Market Issuance Sales Agreement, bolstering its finances. Progress was made on COVID-19 drug candidates with promising animal studies indicating significant effectiveness. However, the company reported a net loss of $8.82 million for the fiscal year, down from $13.45 million the previous year.

NanoViricides, Inc. (NYSE American: NNVC) announced that its drug candidate NV-CoV-2 showed effectiveness against SARS-CoV-2 in a cell culture pseudovirion assay, indicating broad-spectrum pan-coronavirus activity. This suggests the drug could combat evolving variants of the virus. The study revealed NV-CoV-2 inhibits virus infection similarly to a positive control antibody. The company plans to prepare documents for human clinical trials, believing NV-CoV-2 could significantly impact the ongoing pandemic if proven effective.